Gelişmiş Arama

Basit öğe kaydını göster

dc.contributor.authorBarbaros, Mustafa Burak
dc.contributor.authorCan, Özgür Devrim
dc.contributor.authorUcel, Umut İrfan
dc.contributor.authorYücel, Nazlı Turan
dc.contributor.authorÖzkay, Ümide Demir
dc.date.accessioned2019-10-19T14:16:25Z
dc.date.available2019-10-19T14:16:25Z
dc.date.issued2018
dc.identifier.issn1420-3049
dc.identifier.urihttps://dx.doi.org/10.3390/molecules23082072
dc.identifier.urihttps://hdl.handle.net/11421/13151
dc.descriptionWOS: 000445295500237en_US
dc.descriptionPubMed ID: 30126223en_US
dc.description.abstractAtomoxetine is a selective noradrenaline reuptake inhibitor drug. Based on the knowledge that agents increasing monoamine levels in the central nervous system have therapeutic potential for neuropathic pain, it is planned to investigate the possible efficacy of atomoxetine on diabetes-induced hyperalgesia, in this study. Randall-Selitto (mechanical noxious stimuli) and Hargreaves (thermal noxious stimuli) tests were used to evaluate nociceptive perception of rats. Obtained data indicated that streptozotocin-induced diabetes causes significant decreases in the paw withdrawal threshold and paw withdrawal latency values of the animals, respectively. However, atomoxetine administered at 3 mg/kg/day for 7 and 14 days improved these diabetes-induced hyperalgesia responses. Furthermore, antihyperalgesic activity was antagonized with -methyl-para-tyrosine methyl ester, phentolamine, propranolol, and sulpiride pre-treatments. The same effect was not reversed, however, by SCH 23390. These findings demonstrated, for the first time, that atomoxetine possesses significant antihyperalgesic activity on diabetes-induced neuropathic pain and this effect seems to be mediated by - and -adrenergic and D-2/D-3 dopaminergic receptors. Results of this present study seem to offer a new indication for an old drug; atomoxetine, but these preclinical data should first be confirmed with further well-designed clinical trials.en_US
dc.description.sponsorshipAnadolu University Scientific Research Projects Commission [1705S549, 1805S200]en_US
dc.description.sponsorshipThis research was supported from the Anadolu University Scientific Research Projects Commission (Project No: 1705S549 and Project No: 1805S200).en_US
dc.language.isoengen_US
dc.publisherMDPIen_US
dc.relation.isversionof10.3390/molecules23082072en_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAtomoxetineen_US
dc.subjectCatecholamineen_US
dc.subjectHargreaves Testen_US
dc.subjectHyperalgesiaen_US
dc.subjectNeuropathyen_US
dc.subjectRandall-Selitto Testen_US
dc.titleAntihyperalgesic Activity of Atomoxetine on Diabetes-Induced Neuropathic Pain: Contribution of Noradrenergic and Dopaminergic Systemsen_US
dc.typearticleen_US
dc.relation.journalMoleculesen_US
dc.contributor.departmentAnadolu Üniversitesi, Eczacılık Fakültesi, Farmakoloji Anabilim Dalıen_US
dc.identifier.volume23en_US
dc.identifier.issue8en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.contributor.institutionauthorCan, Özgür Devrim
dc.contributor.institutionauthorÖzkay, Ümide Demir


Bu öğenin dosyaları:

Thumbnail

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster